Does Medicare Cover Ozempic? – Senior Affair Magazine
Medicare Part D provides coverage for Ozempic (semaglutide) when it is prescribed for managing type 2 diabetes. However, it is important to note that Medicare does NOT cover Ozempic or other GLP-1 medications when they are prescribed solely for weight loss. This remains a significant gap in coverage as of 2024.
Ozempic for Diabetes: Covered
Ozempic is FDA-approved for the treatment of type 2 diabetes and is included in Medicare Part D plans that list it on their formulary. The cost you incur will depend on your plan’s tier structure, with Ozempic typically classified as a Tier 3 or Tier 4 medication, which involves higher cost-sharing.
Wegovy for Weight Loss: Not Covered (Yet)
Wegovy is essentially the same drug (semaglutide) but at a higher dosage, specifically approved for chronic weight management. Unfortunately, Original Medicare and most Part D plans do not cover Wegovy, as Congress has yet to authorize Medicare coverage for weight loss medications. Some Medicare Advantage plans have started to include coverage for obesity drugs, but this is still relatively uncommon.
Mounjaro, Zepbound, and Other GLP-1 Drugs
- Mounjaro (tirzepatide) — covered by Part D when prescribed for type 2 diabetes
- Zepbound (tirzepatide) — the same drug as Mounjaro but at an obesity-approved dosage; not covered for weight loss only
- Rybelsus (oral semaglutide) — covered for type 2 diabetes under Part D
Potential Future Coverage
There is ongoing legislative discussion regarding the inclusion of obesity drug coverage in Medicare. The Treat and Reduce Obesity Act (TROA) has been introduced in Congress multiple times. As GLP-1 drugs gain recognition as effective medical treatments for obesity, it is anticipated that coverage will expand. For the latest updates, keep an eye on Medicare.gov.
Reducing Your Ozempic Costs
- Manufacturer savings programs (NovoCare) may help lower out-of-pocket expenses
- Annually compare Part D plans at Medicare.gov, as formularies and costs can vary
- The Extra Help (LIS) program can reduce drug costs for low-income beneficiaries
Medicare Part D provides coverage for Ozempic (semaglutide) when it is prescribed for managing type 2 diabetes. However, it is important to note that Medicare does NOT cover Ozempic or other GLP-1 medications when they are prescribed solely for weight loss. This remains a significant gap in coverage as of 2024.
Ozempic for Diabetes: Covered
Ozempic is FDA-approved for the treatment of type 2 diabetes and is included in Medicare Part D plans that list it on their formulary. The cost you incur will depend on your plan’s tier structure, with Ozempic typically classified as a Tier 3 or Tier 4 medication, which involves higher cost-sharing.
Wegovy for Weight Loss: Not Covered (Yet)
Wegovy is essentially the same drug (semaglutide) but at a higher dosage, specifically approved for chronic weight management. Unfortunately, Original Medicare and most Part D plans do not cover Wegovy, as Congress has yet to authorize Medicare coverage for weight loss medications. Some Medicare Advantage plans have started to include coverage for obesity drugs, but this is still relatively uncommon.
Mounjaro, Zepbound, and Other GLP-1 Drugs
- Mounjaro (tirzepatide) — covered by Part D when prescribed for type 2 diabetes
- Zepbound (tirzepatide) — the same drug as Mounjaro but at an obesity-approved dosage; not covered for weight loss only
- Rybelsus (oral semaglutide) — covered for type 2 diabetes under Part D
Potential Future Coverage
There is ongoing legislative discussion regarding the inclusion of obesity drug coverage in Medicare. The Treat and Reduce Obesity Act (TROA) has been introduced in Congress multiple times. As GLP-1 drugs gain recognition as effective medical treatments for obesity, it is anticipated that coverage will expand. For the latest updates, keep an eye on Medicare.gov.
Reducing Your Ozempic Costs
- Manufacturer savings programs (NovoCare) may help lower out-of-pocket expenses
- Annually compare Part D plans at Medicare.gov, as formularies and costs can vary
- The Extra Help (LIS) program can reduce drug costs for low-income beneficiaries
